Form 4: Viridian Therapeutics CEO Stephen Mahoney Acquires 21,400 Shares

Stephen Mahoney, President and CEO of Viridian Therapeutics, Inc., recently purchased 21,400 shares of common stock at a price of $23.33 per share.

Summary

• On September 27, 2024, Stephen F. Mahoney, the President and CEO of Viridian Therapeutics, Inc., acquired 21,400 shares of the company's common stock.
• The shares were purchased at a price of $23.33 per share.
• Following the transaction, Mr. Mahoney directly owns 21,400 shares of Viridian Therapeutics, Inc.
• A Power of Attorney was executed on September 30, 2024, granting Thomas Beetham, Seth Harmon, and Jennifer Tousignant the authority to execute Forms 3, 4, and 5 on behalf of Stephen Mahoney in accordance with Section 16(a) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. CEO stock purchases are generally viewed positively.

Stakeholder Impact

• The stock purchase by the CEO could positively influence shareholder sentiment.

Key Dates